Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target ...

Amin covers the Healthcare sector, focusing on stocks such as Ocular Therapeutix, Apellis Pharmaceuticals, and BridgeBio Pharma. The word on The Street in general, suggests a Strong Buy analyst ...

HC Wainwright also issued estimates for Entrada Therapeutics’ Q4 2024 earnings at ($0.66) EPS and FY2024 earnings at $1.04 EPS. Skip to main content Analyst Ratings ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Free Report) – HC Wainwright lifted their FY2024 earnings estimates for Karyopharm Therapeutics in a research note issued on Tuesday, November 5th.

Dyne Therapeutics Inc. 4.27% $2.94B ...

After hours: November 13 at 4:47 PM EST Loading Chart for PSTV ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sanofi S.A. Part Cert 0.06% €8.19M ...

Apellis Pharma has become the first company to claim FDA approval for a drug to treat geographic atrophy (GA), a sight-robbing condition that accompanies age-related macular degeneration (AMD ...